ERBB2 and breast cancer: Indeed, we have previously demonstrated that treatment with NK activators, such as tilorone, exerts an anti-tumor effect on TUBO cells and their cancer stem cell-enriched tumorspheres in vivo [47], highlighting the efficacy of NK activation in our Her2+ transplantable mammary cancer model.